Literature DB >> 1735737

Impact of laparotomy finding of significant intraabdominal adhesions on the surgically defined complete response rate to subsequent salvage intraperitoneal chemotherapy.

M Markman1, W Jones, J L Lewis, S Rubin, T Hakes, B Reichman, R Barakat, J Curtin, L Almadrones, W Hoskins.   

Abstract

One possible explanation for the failure of the high concentrations of cytotoxic agents achieved following intraperitoneal (i.p.) drug delivery to produce a favorable response in patients with ovarian cancer is the inability of the drug-containing fluid to be adequately distributed throughout the peritoneal cavity, usually because of intraabdominal adhesion formation. To evaluate the influence of the severity of adhesions, observed at the time of laparotomy performed immediately preceding the initiation of i.p. therapy, on the ability to achieve a surgically defined complete response (S-CR), we retrospectively reviewed the operative reports of 70 patients with small-volume residual ovarian cancer treated on one of three phase-2 salvage i.p. trials at the Memorial Sloan-Kettering Cancer Center. The S-CR rate in the 36 patients with limited adhesion formation observed upon entering the peritoneal cavity was 28%, compared to 35% in the 34 patients with extensive adhesions (P greater than 0.05). In 33 patients treated with a phase-2 cisplatin-based i.p. program, who had previously responded to systemic platinum, 47% (8/17) and 44% (7/16) of those with limited and extensive adhesions, respectively, achieved a S-CR (P greater than 0.05). We conclude that the presence of extensive adhesions observed within the peritoneal cavity at the time of a laparotomy performed immediately prior to the initiation of i.p. therapy does not have a negative impact on the potential to achieve an S-CR, assuming it is technically feasible to lyse all significant adhesions prior to the completion of the operative procedure.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1735737     DOI: 10.1007/bf01187507

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  9 in total

1.  Intraperitoneal contrast infusion for assessment of intraperitoneal fluid dynamics.

Authors:  N R Dunnick; R B Jones; J L Doppman; J Speyer; C E Myers
Journal:  AJR Am J Roentgenol       Date:  1979-08       Impact factor: 3.959

Review 2.  Intraperitoneal chemotherapy.

Authors:  M Markman
Journal:  Semin Oncol       Date:  1991-06       Impact factor: 4.929

3.  Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin.

Authors:  M Markman; B Reichman; T Hakes; W Jones; J L Lewis; S Rubin; L Almadrones; W Hoskins
Journal:  J Clin Oncol       Date:  1991-10       Impact factor: 44.544

4.  Intraperitoneal cisplatin and cytarabine in the treatment of refractory or recurrent ovarian carcinoma.

Authors:  M Markman; T Hakes; B Reichman; W Hoskins; S Rubin; W Jones; L Almadrones; E L Yordan; J Eriksson; J L Lewis
Journal:  J Clin Oncol       Date:  1991-02       Impact factor: 44.544

5.  The effect of volume on the distribution of substances instilled into the peritoneal cavity.

Authors:  N Rosenshein; D Blake; P A McIntyre; T Parmley; T K Natarajan; J Dvornicky; E Nickoloff
Journal:  Gynecol Oncol       Date:  1978-02       Impact factor: 5.482

Review 6.  Intraperitoneal antineoplastic agents for tumors principally confined to the peritoneal cavity.

Authors:  M Markman
Journal:  Cancer Treat Rev       Date:  1986-12       Impact factor: 12.111

7.  Intraperitoneal cisplatin and etoposide in the treatment of refractory/recurrent ovarian carcinoma.

Authors:  B Reichman; M Markman; T Hakes; W Hoskins; S Rubin; W Jones; L Almadrones; M Ochoa; D Chapman; P Saigo
Journal:  J Clin Oncol       Date:  1989-09       Impact factor: 44.544

8.  Phase II trial of intraperitoneal mitoxantrone in the management of refractory ovarian cancer.

Authors:  M Markman; M George; T Hakes; B Reichman; W Hoskins; S Rubin; W Jones; L Almadrones; J L Lewis
Journal:  J Clin Oncol       Date:  1990-01       Impact factor: 44.544

9.  Intraperitoneal cisplatin with systemic thiosulfate protection.

Authors:  S B Howell; C L Pfeifle; W E Wung; R A Olshen; W E Lucas; J L Yon; M Green
Journal:  Ann Intern Med       Date:  1982-12       Impact factor: 25.391

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.